Can nanobodies be the key to defeating antibiotic resistance?

Introduction

Gram-negative bacteria pose a significant global health threat due to their antibiotic resistance. One major factor is the New Delhi metallo-β-lactamase-1 (NDM-1) enzyme, which neutralizes carbapenem antibiotics, a last line of defence against bacterial infections. A recent study published in Molecules highlights nanobody-based inhibitors as a promising solution to target NDM-1 and restore antibiotic efficacy.

Key findings from the study include

• High specificity and affinity: Nanobodies were engineered to target and inhibit NDM-1 effectively. One particular nanobody exhibited nanomolar binding affinity (KD = 2.1 nM), demonstrating a strong 10-fold binding interaction with NDM-1, as shown in the figure.

• Enhanced bacterial inhibition: Combined with carbapenem antibiotics, the nanobody inhibitors restored antibiotic effectiveness by 85%, significantly improving bacterial clearance in vitro.
• Superior stability: Unlike conventional antibodies, nanobodies retained their structural integrity after exposure to 70°C for 1 hour and remained active for over 30 days in solution, making them ideal for clinical applications.

Why are nanobodies ideal for tackling NDM-1?

• Small size (15 kDa): Nanobodies penetrate bacterial biofilms and access hidden epitopes, which traditional antibodies struggle to reach.
• High stability: Their robustness allows them to function in harsh conditions where traditional antibodies degrade.
• Cost-effective production: Easily expressed in microbial systems such as E. coli, ensuring scalability and affordability.

This research underscores nanobodies’ potential in antibiotic resistance mitigation, offering a targeted, scalable, and stable approach to tackling multidrug-resistant bacteria.

Read the full research here: https://www.mdpi.com/1420-3049/29/7/1431